This company listing is no longer active
RFL Stock Overview
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Tyme Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.28 |
| 52 Week High | US$0.96 |
| 52 Week Low | US$0.20 |
| Beta | 0.92 |
| 1 Month Change | -16.41% |
| 3 Month Change | 22.50% |
| 1 Year Change | -68.08% |
| 3 Year Change | -82.10% |
| 5 Year Change | n/a |
| Change since IPO | -88.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| RFL | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 17.7% | -5.9% | -1.7% |
| 1Y | -68.1% | -21.4% | -0.2% |
Return vs Industry: RFL underperformed the German Biotechs industry which returned -9.5% over the past year.
Return vs Market: RFL underperformed the German Market which returned -25.4% over the past year.
Price Volatility
| RFL volatility | |
|---|---|
| RFL Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RFL has not had significant price volatility in the past 3 months.
Volatility Over Time: RFL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 13 | Richie Cunningham | www.tymeinc.com |
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors.
Tyme Technologies, Inc. Fundamentals Summary
| RFL fundamental statistics | |
|---|---|
| Market cap | €49.40m |
| Earnings (TTM) | -€24.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs RFL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RFL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$24.19m |
| Earnings | -US$24.19m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RFL perform over the long term?
See historical performance and comparison